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The Evolving Role of Inflammatory Biomarkers
in Risk Assessment After Stent Implantation
Giampaolo Niccoli, MD, PHD, Rocco A. Montone, MD, Giuseppe Ferrante, MD, PHD,
Filippo Crea, MD, PHD
Rome, Italy
The main adverse reactions to coronary stents are in-stent restenosis (ISR) and stent thrombosis. Along
with procedural factors, individual susceptibility to these events plays an important role. In particular, in-
flammatory status, as assessed by C-reactive protein levels, predicts the risk of ISR after bare-metal stent
implantation, although it does not predict the risk of stent thrombosis. Conversely, C-reactive protein levels
fail to predict the risk of ISR after drug-eluting stent (DES) implantation, although they appear to predict
the risk of stent thrombosis. Of note, DES have abated ISR rates occurring in the classical 1-year window,
but new concern is emerging regarding late restenosis and thrombosis. The pathogenesis of these late
events seems to be related to delayed healing and allergic reactions to polymers, a process in which eosin-
ophils seem to play an important role by enhancing restenosis and thrombosis. The identification of high-
risk individuals based on biomarker assessment may be important for the management of patients receiv-
ing stent implantation. In this report, we review the evolving role of inflammatory biomarkers in predicting
the risk of ISR and stent thrombosis. (J Am Coll Cardiol 2010;56:1783–93) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.045u
p
i
w
l
l
i
t
I
I
F
t
(
v
p
i
m
s
i
l
n
(
b
itent implantation has substantially replaced plain old
alloon angioplasty for the treatment of coronary stenosis
ecause of better angiographic results and fewer complica-
ions. Unfortunately, in-stent restenosis (ISR) has largely
imited the efficacy of bare-metal stents (BMS), because it
ccurs in up to 30% of patients treated with BMS. The
ntroduction of drug-eluting stents (DES) significantly
educed the incidence of ISR as compared with BMS,
lthough ISR still occurs (7% to 13%) depending on lesion
nd procedural features (1). Furthermore, new concerns are
merging with DES regarding late ISR and stent throm-
osis (ST) (2–5).
Along with technical/mechanical factors, the individual
esponse to stent implantation is another often underesti-
ated important player in ISR and ST (Fig. 1). Interest-
ngly, several experimental studies have demonstrated that
ocal and systemic inflammation plays a pivotal role in the
athogenesis of ISR, promoting neointimal proliferation
hrough the stent struts (6,7). Moreover, recent evidence
uggests a role for inflammation in the pathogenesis of ST
4,8–10). In the clinical arena, a marker of systemic inflam-
ation, C-reactive protein (CRP), has been shown to
redict clinical and angiographic outcomes in patients
rom the Institute of Cardiology, Catholic University of the Sacred Heart, Rome,
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ccepted June 28, 2010.ndergoing BMS implantation or plain old balloon angio-
lasty (11,12). In contrast, the relation between systemic
nflammation and DES restenosis remains controversial,
hereas recent observations suggest an association of CRP
evels with ST (10,13). Finally, allergic inflammation,
argely mediated by eosinophils, has recently been involved
n adverse reactions to DES (4,8). In this report, we review
he evolving role of inflammatory biomarkers in predicting
SR and ST.
SR: An Old Problem Incompletely Solved by DES
rom a pathologic point of view, neointimal proliferation is
he leading mechanism involved in the pathogenesis of ISR
6,7). After an acute inflammatory reaction, which occurs
ery early after stent implantation, the metal stent struts
romote a “foreign-body” reaction, with migration into the
ntima and subsequent proliferation of vascular smooth
uscle cells (VSMC) (14).
Drug-eluting stents were designed to obtain a site-
pecific delivery of drugs with antiproliferative and anti-
nflammatory properties, able to counteract the mechanisms
eading to ISR. In particular, each DES comprises 3 compo-
ents: the stent platform, the active drug, and the drug carrier
usually a polymer). Of note, polymer-free DES have recently
een introduced into clinical practice; in these DES, the drug
s eluted directly from reservoirs inside the stent (15). First-
eneration DES were coated with either sirolimus (sirolimus-
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Biomarkers and Adverse Reaction to Stent November 23, 2010:1783–93eluting stent [SES]) or paclitaxel
(paclitaxel-eluting stent [PES]),
able to block VSMC migration
and proliferation.
Despite exciting results being
reported during the initial trials
evaluating the safety and efficacy of
first-generation DES, the real-
world use of DES has clearly
shown that ISR still occurs after
DES implantation, the temporal
window of ISR presentation being
wider compared with that of
BMS. Some studies indeed have
raised the possibility of a late
catch-up phenomenon (2,3,16,17),
as if antiproliferative drugs might
simply delay the occurrence of
ISR; however, other studies have
failed to demonstrate a significant
occurrence of late restenosis after
DES implantation (18,19), thus
prompting further investigations.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CRP  C-reactive protein
DES  drug-eluting
stent(s)
ECP  eosinophil cationic
protein
ISR  in-stent restenosis
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
Figure 1 Mechanisms Involved in Adverse Reaction to Stents
Multiple interacting mechanisms including stent characteristics, procedural factors
*Factor involved mainly or exclusively in drug-eluting stent (DES) restenosis. CTO T: An Expanding Concern With DES
near-complete re-endothelialization of stent struts has
een demonstrated to occur 3 to 4 months after coronary
MS stent implantation (7). In contrast, after DES
mplantation, the eluted drug, besides affecting neointima
ormation, has been shown to affect arterial healing with
elayed re-endothelialization, resulting in a prothrombo-
enic environment and the need for prolonged double
ntiplatelet therapy (20). Furthermore, hypersensitivity
eactions against the polymer have been associated with
hrombotic complications probably mediated by persis-
ent inflammation and late malapposition (4,20). Finally,
nhanced tissue factor expression induced by both siroli-
us and paclitaxel, as well as persistent endothelial
ysfunction, may contribute to the pathophysiology of
ES-associated ST (21–23).
ES Versus BMS Adverse Reactions:
he Case for a Distinction
hereas the occurrence of early adverse reactions to coro-
ary stents seems to be mainly related to procedural and
idual susceptibility, and inflammation may lead to adverse reaction to stents.
nic total occlusion; SVG  saphenous vein graft., indiv
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November 23, 2010:1783–93 Biomarkers and Adverse Reaction to Stentechnical factors for both DES and BMS (24), a growing
ody of evidence suggests that late adverse reactions to DES
nd BMS are different in relation to pathogenesis, his-
opathologic features, and clinical presentation (Fig. 2).
Pathologic examinations of specimens derived from hu-
an coronary atherectomy revealed that DES restenosis was
ssociated with a larger amount of old thrombus and
brinoid compared with BMS, possibly as a consequence of
he delayed tissue healing induced by the eluted drug (25).
ndeed, incomplete endothelialization and the presence of
hrombus were more frequently found at angioscopy up to 2
ears after percutaneous coronary intervention (PCI) for
atients with DES but not BMS (26). Otherwise, the
ncreased thrombotic burden in DES-treated patients might
Figure 2 ISR of BMS or DES: Role of Biomarkers and Potential
The evolving role of biomarkers in risk assessment after bare-metal stent (BMS) o
mation, are shown. The contribution of specific cell types is also shown in the diff
events may complicate the healing process after DES implantation. Figure illustrat
lished reports. ()  probably useful in risk assessment but little evidence from p
about use in risk assessment. CRP  C-reactive protein; ECP  eosinophil cationlso be related to hypersensitivity reaction to stent polymer
4). Furthermore, a recent study showed different smooth
uscle cell phenotypes in specimens of restenotic tissue
btained from BMS or DES ISR (27). Optical coherence
omography (OCT) studies confirmed that DES restenosis
ay be composed of different tissues, showing the presence
f neointimal components with different optical properties
28). In contrast, neointimal hyperplasia after BMS implan-
ation is recognized by OCT as homogeneous tissue (29).
f interest, coronary segments treated with DES showed
he angioscopic evidence of yellow neointima coverage at
0-month follow-up, suggesting nouveau atherosclerosis,
hich is associated with increased thrombotic burden (30).
imilar findings have been obtained by using OCT (31) and
apy Targeting Inflammation
eluting stent (DES) implantation, along with potential therapies targeting inflam-
hases of response of the vessel wall against the stent. Of note, late thrombotic
Craig Skaggs. ()  useful for risk assessment with much evidence from pub-
ed reports. (/)  not useful in risk assessment. (?)  data are lacking
ein; ISR  in-stent restenosis.Ther
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Biomarkers and Adverse Reaction to Stent November 23, 2010:1783–93ay be related to increased lipid deposition within the
rterial wall, leading to an accelerated atherosclerosis with a
igher thrombogenic potential. Accordingly, clinical pre-
entation of symptomatic ISR was observed with myocardial
nfarction (MI) more often with DES than with BMS (32).
Past observations have indicated that the peak rate of
MS restenosis occurs at 6 to 9 months, and this time frame
as used to evaluate DES efficacy. However, data about the
ime course of DES restenosis are more limited. A recent
tudy by Byrne et al. (16) investigated the notion of late
atch-up restenosis, evaluating the time course of ISR
ollowing implantation of DES, with an angiographic
ollow-up at 6 to 8 months and at 2 years. Interestingly,
ES showed an increasing late luminal loss beyond 6 to 8
onths, which was less pronounced for polymer-free DES
ompared with permanent-polymer DES, suggesting a crit-
cal role of polymer-induced inflammation in determining
ate DES restenosis.
Similarly, the temporal course of ST after BMS implan-
ation is quite different compared with that observed after
ES implantation. Although acute, subacute, and late ST
1 year) rates are similar for BMS and DES, concerns
ave been raised about a higher occurrence of very late ST
fter DES implantation (5,33), particularly following cessa-
ion of double antiplatelet therapy (24,34). Whereas acute,
ubacute, and late ST appear to share common procedure-
elated mechanisms for both BMS and DES, very late ST
eems to be a consequence of an abnormal reaction of the
essel wall against the polymer, as suggested by post-
ortem observations that showed eosinophilic inflamma-
ion, delayed healing, and strut malapposition of throm-
osed stents (4,20). The occurrence of coronary aneurysms
bserved following DES implantation is also probably
elated to late stent malapposition (4,35). Finally, local
mmunosuppression induced by the eluted drug has been
uggested as a favoring factor for stent-related infections
ith DES (36), which may be complicated with mycotic
neurysms.
Although cessation of dual antiplatelet therapy has been
ssociated with ST, it is worth noting that ST may occur in
atients on double antiplatelet therapy, thus suggesting that
ther mechanisms may be involved. In particular, many
iologic observations suggest a close link between inflam-
ation and platelet reactivity or blood thrombogenicity
37), although recent observations suggest beneficial effects
f antiplatelet drugs being mediated in part by anti-
nflammatory effects (38). Interestingly, acute infection-
nflammation has been linked in an observational study with
T, especially in those patients with a low-risk profile for
T based on known risk factors (39).
Taken together, these findings suggest that after a first
hase when the eluted drug is able to counteract the
nflammatory reaction following stent implantation, a sec-
nd window of inflammation, perhaps enhanced by the
resence of the stent polymer, may contribute to delayed
SR by favoring late neointimal proliferation and ST. This pecond window of inflammation is reminiscent of the late
hase reaction, also called type IV allergic reaction or
elayed-type hypersensitivity with infiltration of T helper 2
ymphocytes and eosinophils (40).
echanical and Patient-Related
redictors of ISR and ST
any studies have assessed predictors of ISR or ST after
MS or DES implantation. Lesion-related (type C lesion,
essel size, and lesion severity) and procedure-related (num-
er of stents implanted and angiographic, intravascular
ltrasound [IVUS], or pressure-derived indexes of stent
xpansion at stent level) factors have been associated with
SR after BMS implantation, and most of them have been
onfirmed to play a role also after DES implantation
41,42). Among patient-related factors, diabetes and renal
ailure increase ISR rates after both BMS and DES implan-
ation (41,43).
Stent thrombosis shares most of the previously described
redictors of ISR (44). It is worth noting, however, that
ost BMS-related ST occurs early (30 days) and is mainly
ssociated with procedural factors (stent underexpansion,
tent length, dissection, and residual disease at the stent
dges), but late, and particularly very late, DES-related ST
as been mainly associated with patient-related factors
poor response to antiplatelet drug, premature discontinua-
ion of antiplatelet therapy, diabetes, malignancy, renal
ailure, and acute coronary syndrome at presentation) (45).
rognostic Value of Inflammatory
iomarkers With BMS
everal inflammatory biomarkers have been investigated in
he setting of coronary stenting to stratify the risk of both
ngiographic and clinical outcomes. CRP is the most widely
tudied biomarker in patients undergoing PCI and repre-
ents a sensitive marker of systemic inflammation. CRP is
n acute-phase protein produced mainly by hepatocytes in
esponse to stimulation by inflammatory cytokines, primar-
ly interleukin (IL)-6 (46). CRP has been shown to predict
uture cardiac events in both primary and secondary preven-
ion studies (47,48). Interestingly, CRP has also been
emonstrated to be an excellent marker of post-stenting
nflammatory status. Indeed, the levels of CRP increase
fter PCI in a time-dependent manner, peaking at 48 h, and
he magnitude of CRP change after the procedure has been
hown to predict ISR in patients undergoing BMS deploy-
ent (49).
Notably, a few studies only evaluated serum levels of CRP
fter stent implantation over time, by serial assessment.
RP protein levels have been shown to be persistently
igher at 6 months in those patients with ISR in some
tudies (50) but not in others (51), thus suggesting that
aseline or post-procedural levels of CRP may help in
rediction of ISR more than that at follow-up.
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November 23, 2010:1783–93 Biomarkers and Adverse Reaction to StentA recently published meta-analysis of 9 studies involving
,747 patients undergoing BMS implantation showed that
igher baseline CRP serum levels were a significantly
redictor of angiographic restenosis (odds ratio: 1.59, 95%
onfidence interval: 1.21 to 2.07; p 0.01) (52) (Fig. 3). Of
nterest, Hoshida et al. (50) demonstrated that in patients
ith stable angina, increased pre-procedural CRP levels
ere an important risk factor for ISR only among patients
ho were not receiving statins, but not among treated
atients. Accordingly, Walter et al. (53) showed an inter-
ction among admission CRP levels, statin therapy, and rate
f restenosis in patients undergoing BMS implantation.
inally, Hong et al. (54) showed that plaque morphology is
nother factor modulating the link between inflammation
nd ISR, concluding that the combination of soft plaque
etected by IVUS and elevated CRP levels was the most
ignificant independent predictor of ISR.
The association between CRP and BMS-related ISR is
robably accounted for by the fact that acute-phase proteins
epresent a marker of hyper-responsiveness to inflammatory
timuli, thus suggesting that pre-procedural activation of
nflammatory cells may play a role in the modulation of the
essel wall response to injuries derived from stent deploy-
Figure 3 Forest Plot of Studies Assessing Relation Between Pr
Overall and each study estimate of the odds ratio (OR) of the angiographic resteno
zontal lines  95% confidence intervals (CIs). High CRP levels mean that the leve
ranged from 0.3 to 1.0 mg/dl according to the study. Modified from Ferrante et alent (11). The association between CRP and ISR might
lso be explained by the direct proinflammatory effects of
RP on endothelial cells (55). However, mendelian trials
valuating patients with genetically elevated CRP levels
ailed to demonstrate a pathogenetic role for CRP in
ardiovascular diseases (56). Accordingly, a study by Zee et
l. (57) found no association between CRP polymorphisms
nd restenosis after balloon angioplasty.
Importantly, both baseline and post-procedural peak
evels of CRP have been associated with the overall rate of
ajor cardiovascular events (MACE) after BMS implanta-
ion (53,58), although no large study has specifically as-
essed the association of CRP levels with ST after BMS. In
tudies without systematic angiographic follow-up, it is
bviously impossible to determine whether the association
ith MACE is due to stent-related events or to atheroscle-
osis progression in native coronary arteries.
Other inflammatory biomarkers have been investigated for
isk prediction after BMS implantation. In particular, matrix
etalloproteinase (MMP)-2, MMP-9, and pregnancy-
ssociated plasma protein A, involved in extracellular matrix
egradation and VSMC migration following vascular in-
ury, have been associated with angiographic ISR (59–61).
cedural CRP Levels and BMS Restenosis
sociated with high versus low levels of pre-procedural CRP. Boxes  OR; hori-
P was greater than the cut-off value specified in each study. The cut-off value
Abbreviations as in Figure 2.e-Pro
sis as
l of CR
. (52).
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Biomarkers and Adverse Reaction to Stent November 23, 2010:1783–93urthermore, platelet and neutrophil activation as assessed
y sCD40L and glycosylphosphatidylinositol-80 levels, re-
pectively, was associated with ISR after BMS implantation
62,63). Finally, fibrinogen and plasminogen activator in-
ibitor (PAI)-1 activity, proteins involved in the coagula-
ion system that are usually considered inflammatory bi-
markers, have been associated with ISR after BMS
mplantation (64,65). Overall, the results are less robust
han that observed with CRP. This may be related to their
hort half-lives, which increase measurement variability. In
ontrast, the long half-life of CRP (approximately 19 h)
akes the measurements more reproducible (66).
Furthermore, several polymorphisms of inflammation-
elated genes have been associated with an increased risk of
estenosis (67–69). In particular, a single-nucleotide poly-
orphism of the cyclin-dependent kinase inhibitor p27kip1,
key regulator of VSMC and leukocyte proliferation, has
een found to be associated with ISR rate (67), as well as a
olymorphism of toll-like receptor 2, a molecule involved in
he interaction between the immune system and infective
athogens (68).
Taken together, studies performed in the setting of BMS
mplantation have strengthened the role of inflammatory
iomarkers in risk prediction of ISR. Because of its pro-
onged half-life, as compared with that of other inflamma-
ory biomarkers, CRP has been the most investigated.
lthough inflammatory biomarkers do not specifically pre-
ict ISR because they may also predict progression and
estabilization of atherosclerosis in native coronary arteries,
ata coming from angiographic studies clearly show that
oth baseline and post-procedural CRP levels are useful for
he identification of patients at higher risk of restenosis after
MS. Whether CRP levels are associated with ST cannot
e extrapolated by published studies.
rognostic Value of
nflammatory Biomarkers With DES
ecent studies evaluated the association between CRP or
ther inflammatory biomarkers and angiographic and clin-
RP Levels and Adverse Reaction to Stent in Patients UndergoingTable 1 CRP Levels and Adverse Reaction to Stent in Patients
First Author (Ref. #) Year Stent
Baseline CRP
Dibra et al. (71) 2005 SES
Park et al. (70) 2007 SES/PES
Niccoli et al. (83) 2009 SES/PES
Park et al. (10) 2009 SES/PES
Choi et al. (76) 2010 SES/PES
Delhaye et al. (77) 2010 SES/PES
Post-procedural CRP changes
Dibra et al. (71) 2005 SES
Gaspardone et al. (58) 2006 SES/PES/DEX
Kang et al. (72) 2009 SES/PESCS  acute coronary syndrome; CRP  C-reactive protein; DES  drug-eluting stent(s); DEX  dexamet
ngina; SES  sirolimus-eluting stent(s); ST  stent thrombosis; TVR  target vessel revascularization; Ucal outcomes after DES deployment (Table 1). In contrast
ith findings of studies on BMS, pre-procedural serum
RP levels do not appear to predict ISR in this setting. Park
t al. (70) failed to show increased ISR and late loss among
ertiles of baseline CRP on 1,650 consecutive patients
ndergoing successful DES implantation. The prognostic
alue of the magnitude of CRP changes after DES implan-
ation has also been investigated. Gaspardone et al. (58)
rospectively enrolled 160 consecutive patients with stable
ingle-vessel disease undergoing BMS, SES, PES, or
examethasone-eluting stent (DEX) implantation and as-
essed serum CRP changes at 48 h compared with baseline.
re-procedural CRP levels were similar among all groups of
atients, and CRP levels significantly increased after coro-
ary stenting without any difference across the 4 groups.
nterestingly, the incidence of angiographic binary resteno-
is at 12 months was significantly lower in the SES and PES
roups compared with that of BMS and DEX, suggesting
hat the lower rate of ISR observed after DES deployment
as unlikely to be related to a reduced acute systemic
nflammatory response but rather to a local blunted inflam-
atory response. Dibra et al. (71), enrolling 301 stable or
nstable patients treated with BMS or SES implantation,
howed that a higher CRP change after the procedure was
predictor of ISR in the BMS group but not in the SES
roup. Moreover, a study by Kang et al. (72) failed to
emonstrate an association between changes in CRP or
L-6 levels and neointima hyperplasia evaluated by IVUS,
ollowing SES or PES deployment.
Serum levels of MMP, PAI-1, and complement compo-
ents C3a and C5a have also been evaluated for risk
rediction after DES implantation. Katsaros et al. (73)
emonstrated that baseline MMP-9 and post-procedural
after 24 h) MMP-9 and MMP-2 levels were significantly
igher in patients with ISR at the 6- to 8-month angio-
raphic follow-up compared with those in patients without
SR. Moreover, plasma levels of PAI-1 before and 24 h after
CI were associated with the occurrence of angiographic
SR (74). Finally, Speidl et al. (75) found that serum levels
Implantationrgoing DES Implantation
of Patients
With DES
Clinical
Presentation Predicted Events
149 SA ISR not predicted
1,650 ACS or SA ISR not predicted
200 ACS or SA TVR not predicted
2,691 UA or SA TVR not predicted, ST predicted
1,859 ACS or SA TVR not predicted, ST predicted
936 UA or SA TVR not predicted
149 SA ISR not predicted
121 SA ISR predicted
79 SA ISR not predictedDESUnde
#hasone-eluting stent(s); ISR  in-stent restenosis; PES  paclitaxel-eluting stent(s); SA  stable
A  unstable angina.
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November 23, 2010:1783–93 Biomarkers and Adverse Reaction to Stentf C3a before and 24 h after PCI, as well as baseline C5a
evels, were significantly higher in patients developing ISR
t the 6- to 8-month angiographic follow up.
CRP levels have recently been associated with the risk of
ACE (10,76,77). Park et al. (10) conducted a study on a
arge patient population (n  2,691) with a median
ollow-up of 3.9 years; baseline CRP levels were associated
ith an increased risk of death, MI, and ST, with CRP
evels improving the predictive value above that of clinical,
ngiographic, and procedural factors. Interestingly, this
arge study failed to show an association of baseline CRP
evels with target vessel revascularization.
Taken together, available information suggests that the
redictive role of inflammation for adverse reactions to
tent, as assessed by CRP levels, seems to shift from
estenosis as observed with BMS to thrombotic complica-
ions, including ST with DES. This apparent paradox may
e explained by the following observations. After DES
mplantation, the eluted drug is able to halt the inflamma-
ory reaction leading to restenosis also in patients with
nhanced inflammatory response as revealed by high CRP
evels. In contrast, very late thrombosis occurs when the
rug effect is over; in this setting, an enhanced inflammatory
esponse as revealed by high serum CRP levels, perhaps
riggered by the polymer, may predispose patients to throm-
us formation. With BMS, the lack of drug elution leaves
nopposed the inflammatory reaction, leading to restenosis,
specially in patients with an enhanced inflammatory re-
ponse. In contrast, very late thrombosis is rare, perhaps
ecause of the lack of polymer, and therefore difficult to
redict.
llergic Reaction to Stent Implantation:
New Player
s noted previously, recent evidence supports the notion
hat a localized hypersensitivity reaction to stent compo-
ents may be involved in the inflammatory process follow-
ng stent implantation. Eosinophil infiltrates surrounding
tent struts have been described in ISR tissue of patients
reated with BMS but rarely in post-balloon restenotic
issue (78,79). Notably, histopathologic studies showed that
osinophils are observed among inflammatory cells more
ith DES than with BMS, suggesting that allergy-
ediated inflammation plays a greater role with DES- than
ith BMS-related ISR (80).
Although DES can promote eosinophil recruitment
hrough different mechanisms, available pathologic evidence
upports the notion that hypersensitivity to the polymer is
he most likely mechanism. In fact, polymers have been
hown to produce hypersensitivity reactions in humans and
o promote inflammation when implanted in swine coronary
rteries (81). On the other hand, the hypersensitivity reac-
ion is unlikely to be caused by the eluted drug because
harmacokinetic studies performed in dogs and rabbits
how that the drug is no longer present in the arterial wall after 60 days and because of its anti-inflammatory properties
hat would suppress accumulation of such inflammatory
ells (82).
Accordingly, we have recently shown for the first time
hat enhanced eosinophilic activation at baseline, as assessed
y pre-procedural serum eosinophil cationic protein (ECP)
evels, predicts the clinical outcome after implantation of
rst-generation DES (83). Because the target lesion revas-
ularization (TLR) rate was highly prevalent in the com-
osite end point when compared with death or MI, our
ndings should mainly be applied to TLR.
Notably, eosinophils might play a role not only in ISR
ut also in ST. Indeed, eosinophilic infiltrates may affect
essel remodeling, leading to secondary stent malapposition
nd local thrombosis (4). Moreover, eosinophils can directly
timulate the coagulation pathway and promote platelet
ctivation (84). Virmani et al. (4) initially documented a
ocalized hypersensitivity reaction associated with late in-
tent thrombosis in a patient implanted with an SES.
oreover, Joner et al. (20) reported post-mortem findings
rom a series of 40 patients who died after DES implanta-
ion, showing local hypersensitivity reaction as a risk factor
or late ST. Additional data on hypersensitivity reactions
fter DES deployment were shown by the RADAR (Re-
earch on Adverse Drug Events and Reports) project, which
oncluded that DES may be a cause of systemic and
ntrastent hypersensitivity reactions that, in some cases, have
een associated with late thrombosis and death, confirming
he association among local hypersensitivity reaction,
hrombosis, and lack of intimal healing (9). Finally, a recent
tudy by Cook et al. (8) showed that eosinophilic infiltrates
re more common in thrombi harvested from very late DES
hrombosis as compared with those harvested from other
auses of MI.
The role of eosinophil activation, as assessed by ECP
erum levels, needs to be evaluated more extensively in the
etting of coronary stenting with BMS. Indeed, eosinophil
nfiltrates have been demonstrated around stent struts of
estenotic BMS (78), and positive patch test to metal allergy
as been associated with restenosis of BMS (85).
he Evolving Role of Biomarkers in
isk Assessment After Stent Implantation
ased on the different mechanisms of ISR and ST between
ES and BMS, the use of inflammatory biomarkers after
ES needs to be reappraised. Both choice of biomarkers and
iming of measurements need careful reassessment (Fig. 2).
ndeed, CRP measurement before DES implantation may
e useful in the identification of a nonspecific inflammatory
yper-reactivity that may lead to an increased rate of ST
10). CRP may also predict a worse clinical outcome not
elated to stent-related events but rather to the progression
nd destabilization of coronary atherosclerosis, as previously
bserved in subjects without or with pre-existing coronary
rtery disease. The role of new biomarkers such as MMP-9,
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mplantation should be further investigated.
More importantly, biomarkers of hypersensitivity, like
CP, may be useful for the identification of patients at
ncreased risk to develop an allergic response to the stent
olymer (83). Further studies are warranted to evaluate the
rognostic value of biomarkers of allergy not only at baseline
ut also at other time points (for instance, when drug
lution is over) to better detect potential allergic reactions to
olymer or even to metal. Furthermore, other biomarkers
e.g., IL-5, leukotrienes) or diagnostic tests of allergy (e.g.,
ntradermal or patch tests) need to be investigated. Inter-
stingly, patients with allergic patch-test reactions to nickel
nd molybdenum appear to have a higher rate of ISR
ollowing BMS implantation (85).
herapeutic Implications
oth traditional and allergic inflammation may become a
herapeutic target in patients undergoing stent implanta-
ion. Administration of statins or steroids has been sug-
ested to reduce the risk of MACE after BMS. Statins
xhibit well-known anti-inflammatory properties (86); their
eneficial effects in patients undergoing stent deployment
ave been documented in many clinical studies, although
he studies are limited by small sample sizes (87–89). The
RMYDA (Atorvastatin for the Reduction of Myocardial
amage During Angioplasty) studies demonstrated that
atients treated with atorvastatin 40 mg/day either before or
t the time of PCI have a smaller increase in CRP levels
ompared with placebo (87). These acute effects are more
ikely explained by anti-inflammatory rather than lipid-
owering effects. Moreover, a small study with angiographic
ollow-up confirmed a reduced risk for the occurrence of
SR after BMS implantation in patients receiving statin
herapy (90). Accordingly, the LIPS (Lescol Intervention
revention Study) showed that treatment with fluvastatin
0 mg/day in patients undergoing first PCI, with or without
MS implantation, resulted in a 5.3% absolute reduction
nd 22% relative reduction in the risk of MACE during 4
ears of follow-up compared with placebo (89).
Steroids are potent anti-inflammatory agents that may blunt
ytokine-induced VSMC proliferation. The IMPRESS (Im-
unosuppressive Therapy for the Prevention of Restenosis
fter Coronary Artery Stent Implantation) study evaluated
he administration of a systemic steroid therapy (oral pred-
isone 72 h after PCI, 1 mg/kg for the first 10 days, 0.5
g/kg from day 11 to day 30, and 0.25 mg/kg from day 31
o day 45) in patients undergoing BMS implantation.
mportantly, an inclusion criterion was the presence of
ersistently high CRP levels after the procedure (CRP0.5
g/dl at 72 h). This study showed a striking reduction in
umber of clinical events at 12 months (28% absolute
eduction) and the angiographic restenosis rate at 6 months
7% vs. 33%) as compared with placebo. The use of systemic
teroids after BMS should be further investigated because it pay become an adjunctive therapy to prevent ISR after
MS implantation in patients at high risk for ISR who are
ot suitable for DES (e.g., patients with atrial fibrillation
ho need life-long anticoagulation). However, an impor-
ant issue related to steroid administration is its applicability
n the real-world population. In fact, side effects derived
rom systemic steroid therapy are well known and may
reclude its use in patients with comorbid conditions, such
s diabetes (a major cause of ISR), hypertension, and
ongestive heart failure. In the IMPRESS trial, 15% of
atients among those referred for stent implantation ful-
lled the enrollment criteria (91). Of note, no beneficial
ffect could be detected when the dose of prednisone was
ecreased by nearly one-half (91,92).
Stents releasing steroids, such as DEX, have been de-
igned in the attempt to obtain a pharmacologic modulation
f local inflammation. Yet evidence derived from clinical
tudies has not shown any clinical benefit (93,94). This
ight be due to suboptimal drug concentrations and/or to
he fact that steroids are hydrophilic and therefore sink in
lood rather than being absorbed by the lipophilic arterial
all (95).
The antidiabetic drug pioglitazone, ligand for peroxisome
roliferator-activated receptors, is an anti-inflammatory
rug. Several studies performed in patients with diabetes
ave demonstrated a reduced incidence of ISR and TLR
fter BMS deployment associated with peroxisome
roliferator-activated receptor agonist administration (96–
8). Accordingly, a recent study showed a lower ISR rate in
atients with diabetes treated with DES when pioglitazone
as added to standard treatment (96).
Antiplatelet drugs exhibit anti-inflammatory effects (38).
ccordingly, a recent subanalysis of the CREDO (Clopi-
ogrel for the Reduction of Events During Observation)
rial in patients treated with nonurgent coronary stenting
uggested that the clinical benefit of adding clopidogrel to
spirin was greater in those with higher levels of baseline
RP (99).
Besides treatment targeting “classical” inflammation, spe-
ific therapies for allergic reactions to stent polymer need to
e investigated in the future. Of note, steroids have been
hown to suppress eosinophil survival and activation, reduc-
ng the production of related cytokines. Thus, steroids
ight also be considered in patients with elevated baseline
CP levels. Moreover, recent evidence in animal models
uggests that statins, besides their effects on classical inflam-
ation, may affect hypersensitivity reactions by reducing
osinophilic activation (100). Antileukotriene drugs (leuko-
riene receptor antagonists or 5-lipoxygenase inhibitors)
ay represent another possible therapeutic approach to
urther reduce the allergic response toward the stent poly-
er because leukotrienes are involved in hypersensitivity
eactions (101).
An allergen-specific desensitizing immunotherapy to-
ard stent polymer or the introduction of bioabsorbable
olymers or polymer-free stents represent other promising
t
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eactions to DES (15,102). Bioabsorbable stents may be-
ome another possible tool to prevent ISR and ST
103,104).
Finally, important issues in the attempt to optimize
nti-inflammatory treatment of stent-related adverse events
re administration timing and patient selection. To prevent
MS-related ISR, anti-inflammatory drugs have to be given
arly. In contrast, the time course of DES-related ISR
uggests that the best timing, for an antiallergic treatment,
ight be when the drug elution is over, leaving proinflam-
atory and proallergic effects of the polymer unopposed
Fig. 2). With regard to patient selection, it is critical to
elect patients with intense activation of inflammatory cells,
s detected by systemic levels of inflammatory markers, who
re likely to enjoy the highest benefit from an anti-
nflammatory treatment. Surprisingly, in the past, only a few
rials of anti-inflammatory treatment of stent-related ad-
erse events have based patient enrollment on levels of
nflammatory markers (91).
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